The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader-Willi syndrome: A systematic review.
Nicholas Beng Hui NgYue Wey LowDimple Dayaram RajgorJia Ming LowYvonne Yijuan LimKah Yin LokeYung Seng LeePublished in: Clinical endocrinology (2021)
GLP1-RA appears safe in PWS patients and may have potential benefits for weight, glycaemic and appetite control. Nonetheless, we also highlight a significant gap in the literature on the lack of well-designed studies in this area, which limits the recommendation of GLP1-RA use in PWS patients at present.
Keyphrases
- weight loss
- type diabetes
- end stage renal disease
- rheumatoid arthritis
- body mass index
- physical activity
- newly diagnosed
- ejection fraction
- systematic review
- body weight
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- ankylosing spondylitis
- growth hormone
- patient reported outcomes
- case report
- climate change
- systemic sclerosis
- interstitial lung disease
- patient reported